Seroprevalence of human immunodeficiency virus type I (HIV-1) antibodies in a family-planning population.

Seroprevalence of human immunodeficiency virus type 1 among pregnant women.

Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants.

Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. II. Geographic and ecologic determinants.

Human immunodeficiency virus type I. Infection among dentists.

Evaluation of a solid-phase immunoassay for the simultaneous detection of antibodies to human immunodeficiency virus type 1 and human T-cell lymphotropic virus type I.

Seroprevalence of human immunodeficiency virus infection at sentinel hospitals.

Clonal analysis of murine B cell response to the human immunodeficiency virus type 1 (HIV1)-gag p17 and p25 antigens.

Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses.

Transdominant repressors for human T-cell leukemia virus type I rex and human immunodeficiency virus type 1 rev function.

Community seroprevalence of hepatitis B, C and human immunodeficiency virus in adult population in gojjam zones, northwest Ethiopia.

Morphogenesis of human immunodeficiency virus type 1.

The intra-host evolutionary and population dynamics of human immunodeficiency virus type 1: a phylogenetic perspective.

Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Human immunodeficiency virus and type 2 diabetes.

Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.

Prediction of optimal peptide mixtures to induce broadly neutralizing antibodies to human immunodeficiency virus type 1.

Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as prognostic marker.

Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1.

Human immunodeficiency virus type 2 (HIV2).

Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural RNA.

Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.

Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583-599) of human immunodeficiency virus type 1.

Immunoprecipitation of human immunodeficiency virus type 2 glycoproteins by sera positive for human immunodeficiency virus type 1.

Seroprevalence of Human Immunodeficiency Virus Among Antenatal Women in One of the Institute of Northern India.

Suggest Documents

Seroprevalence of human immunodeficiency virus type 1 among pregnant women.

Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants.

Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. II. Geographic and ecologic determinants.

Human immunodeficiency virus type I. Infection among dentists.

Evaluation of a solid-phase immunoassay for the simultaneous detection of antibodies to human immunodeficiency virus type 1 and human T-cell lymphotropic virus type I.

Seroprevalence of human immunodeficiency virus infection at sentinel hospitals.

Clonal analysis of murine B cell response to the human immunodeficiency virus type 1 (HIV1)-gag p17 and p25 antigens.

Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses.

Transdominant repressors for human T-cell leukemia virus type I rex and human immunodeficiency virus type 1 rev function.

Community seroprevalence of hepatitis B, C and human immunodeficiency virus in adult population in gojjam zones, northwest Ethiopia.

Morphogenesis of human immunodeficiency virus type 1.

The intra-host evolutionary and population dynamics of human immunodeficiency virus type 1: a phylogenetic perspective.

Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Human immunodeficiency virus and type 2 diabetes.

Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.

Prediction of optimal peptide mixtures to induce broadly neutralizing antibodies to human immunodeficiency virus type 1.

Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as prognostic marker.

Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1.

Human immunodeficiency virus type 2 (HIV2).

Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural RNA.

Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.

Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583-599) of human immunodeficiency virus type 1.

Immunoprecipitation of human immunodeficiency virus type 2 glycoproteins by sera positive for human immunodeficiency virus type 1.

Seroprevalence of Human Immunodeficiency Virus Among Antenatal Women in One of the Institute of Northern India.

Seroprevalence of human immunodeficiency virus type I (HIV-1) antibodies in a family-planning population.

Recommend Documents

Follow Us